Financial Services: The Company offers a wide range of financial products and solutions, with presence across both retail and wholesale financing. As of March 31, 2022, the Financial Services business had an AUM of ₹ 65,185 Crores. The Company completed the acquisition of Dewan Housing Finance Ltd. (DHFL) in Sep-2021, creating one of the largest housing finance companies in India. Within retail lending, through its multi-product platform, the company offers home loans, loans for small businesses and loans for working capital to customers in affordable housing and mass affluent segments across Tier I, II and III cities. The Digital Embedded Financing business offers personalized financing solutions to retail customers, through digital assets and partnerships with leading Fintech and Consumer Tech firms. Within wholesale lending, the business provides financing to real estate developers, as well as corporate clients in select sectors.
Piramal Alternatives, the fund management business, provides customised financing solutions to high-quality corporates through – ‘Piramal Credit Fund’, a performing, sector-agnostic credit fund with capital commitment from CDPQ; and ‘IndiaRF’, a distressed asset investing platform with Bain Capital Credit, which invests in equity and/or debt across non-real estate sectors.
In addition, the Company also has a 50% stake in Pramerica Life Insurance – a joint venture with Prudential International Insurance Holdings. PEL also has equity investments in the Shriram Group, a leading financial conglomerate in India.
Pharma: Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network over 100 countries.
PPL includes: Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business, selling over-the-counter products.
PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovator and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the Indian consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, Piramal Pharma Limited received growth equity investment from the Carlyle Group.
In October 2021, the Board of Directors of PEL approved the demerger of the pharmaceuticals business and simplification of the corporate structure to create two industry-focused listed entities in Financial Services and Pharmaceuticals. The demerger and subsequent listing of PPL on the Stock Exchanges is expected to get completed by Q3 FY 2023, subject to shareholders, creditors and necessary regulatory approvals.
Revenues for FY 2022
Net Profit for FY 2022
We strive for a deeper understanding of our domain.
We aspire to do things creatively.
We are empowered to act decisively and create value.
We are consistent in our thought, speech and action.
We protect and enhance the interests of our customers, community, employees, partners and shareholders.
We aspire to be the best, yet strive to be humble.
We strive to achieve market leadership in scale and profitability, wherever we compete.
We aspire to build businesses that anticipate, adapt and endure for generations.
At Piramal Group, our core values of Knowledge, Action, Care and Impact are integral to our guiding philosophy. These values represent our deeply held beliefs and define us at the individual as well as organisational levels. We encourage a deep understanding of these core values and believe in institutionalising them across the organisation to build the distinctive Piramal culture.
We aim to serve our customers, community, employees, partners and all other stakeholders by putting their needs and well-being first.
We aim to make a positive difference through our products, services, customer-centric approach and innovation-led research.
We live by our values in our everyday actions, decisions and conduct, at a personal as well as a professional level.
The Company focuses on two core business verticals – Financial Services & Pharma
FY 2022 Revenues: ` 13,993 Crores
FY 2022 Revenue contribution 52%
FY 2022 Revenue contribution 48%
CDMO: Contract Development and Manufacturing Organization